Scandinavian ChemoTech Q1: Positive clinical performance
Research Update
2023-05-26
11:19
Redeye leaves its comments on Scandinavian ChemoTech following the company’s Q1 2023 report. The report contained no significant surprises, but the company reported slightly lower OPEX than expected. We largely maintain our fair value range.
SA
FE
Sebastian Andersson
Filip Einarsson
Disclosures and disclaimers